{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,9]],"date-time":"2026-09-09T20:13:51Z","timestamp":1788984831494,"version":"build-2803163510"},"reference-count":39,"publisher":"Springer Science and Business Media LLC","issue":"9","license":[{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"DOI":"10.13039\/100004331","name":"Johnson and Johnson","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004331","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Dermatol Ther (Heidelb)"],"published-print":{"date-parts":[[2026,9]]},"DOI":"10.1007\/s13555-026-01834-7","type":"journal-article","created":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T18:10:23Z","timestamp":1782929423000},"page":"4355-4374","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Modified Delphi Consensus Recommendations for the Management of Psoriasis in Asia\u2013Pacific"],"prefix":"10.1007","volume":"16","author":[{"given":"Yoo Sang","family":"Baek","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Siew Eng","family":"Choon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter Anthony","family":"Foley","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tsen Fang","family":"Tsai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jianzhong","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0297-6627","authenticated-orcid":false,"given":"Yukie","family":"Yamaguchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,7,1]]},"reference":[{"issue":"19","key":"1834_CR1","doi-asserted-by":"publisher","first-page":"2437","DOI":"10.3390\/healthcare13192437","volume":"13","author":"D Li","year":"1990","unstructured":"Li D, Fan S, Song J, et al. Global psoriasis burden 1990\u20132021: evolving patterns and socio-demographic correlates in the global burden of disease 2021 update. Healthcare (Basel). 1990;13(19):2437. https:\/\/doi.org\/10.3390\/healthcare13192437.","journal-title":"Healthcare (Basel)"},{"issue":"2","key":"1834_CR2","doi-asserted-by":"publisher","first-page":"222","DOI":"10.5021\/ad.2016.28.2.222","volume":"28","author":"SW Youn","year":"2016","unstructured":"Youn SW, Tsai TF, Theng C, et al. The MARCOPOLO study of ustekinumab utilization and efficacy in a real-world setting: treatment of patients with plaque psoriasis in Asia\u2013Pacific countries. Ann Dermatol. 2016;28(2):222\u201331. https:\/\/doi.org\/10.5021\/ad.2016.28.2.222.","journal-title":"Ann Dermatol"},{"issue":"1","key":"1834_CR3","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1016\/j.jdermsci.2011.03.002","volume":"63","author":"TF Tsai","year":"2011","unstructured":"Tsai TF, Wang TS, Hung ST, et al. Epidemiology and comorbidities of psoriasis patients in a national database in Taiwan. J Dermatol Sci. 2011;63(1):40\u20136. https:\/\/doi.org\/10.1016\/j.jdermsci.2011.03.002.","journal-title":"J Dermatol Sci"},{"issue":"4","key":"1834_CR4","doi-asserted-by":"publisher","first-page":"389","DOI":"10.5021\/ad.2010.22.4.389","volume":"22","author":"YW Lee","year":"2010","unstructured":"Lee YW, Park EJ, Kwon IH, Kim KH, Kim KJ. Impact of psoriasis on quality of life: relationship between clinical response to therapy and change in health-related quality of life. Ann Dermatol. 2010;22(4):389\u201396. https:\/\/doi.org\/10.5021\/ad.2010.22.4.389.","journal-title":"Ann Dermatol"},{"issue":"7","key":"1834_CR5","doi-asserted-by":"publisher","first-page":"A677","DOI":"10.1016\/j.jval.2012.08.446","volume":"15","author":"B Schenkel","year":"2012","unstructured":"Schenkel B, Leartsakulpanitch J, Yue N. PSY1 burdens of psoriasis in the Asia Pacific region: a literature review. Value Health. 2012;15(7):A677\u20138. https:\/\/doi.org\/10.1016\/j.jval.2012.08.446.","journal-title":"Value Health"},{"issue":"1","key":"1834_CR6","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1016\/j.jdermsci.2011.03.002","volume":"63","author":"TF Tsai","year":"2011","unstructured":"Tsai TF, Wang TS, Hung ST, et al. Epidemiology and comorbidities of psoriasis patients in a national database in Taiwan. J Dermatol Sci. 2011;63(1):40\u20136. https:\/\/doi.org\/10.1016\/j.jdermsci.2011.03.002.","journal-title":"J Dermatol Sci"},{"issue":"5","key":"1834_CR7","doi-asserted-by":"publisher","first-page":"713","DOI":"10.1111\/bjd.21768","volume":"187","author":"SE Choon","year":"2010","unstructured":"Choon SE, Wright AK, Griffiths CEM, et al. Incidence and prevalence of psoriasis in multiethnic Johor Bahru, Malaysia: a population-based cohort study using electronic health data routinely captured in the Teleprimary Care (TPC\u00ae) clinical information system from 2010 to 2020*. Br J Dermatol. 2010;187(5):713\u201321. https:\/\/doi.org\/10.1111\/bjd.21768.","journal-title":"Br J Dermatol"},{"key":"1834_CR8","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1016\/j.jdin.2020.10.011","volume":"2","author":"H Goto","year":"2021","unstructured":"Goto H, Nakatani E, Yagi H, Moriki M, Sano Y, Miyachi Y. Late-onset development of psoriasis in Japan: a population-based cohort study. JAAD Int. 2021;2:51\u201361. https:\/\/doi.org\/10.1016\/j.jdin.2020.10.011.","journal-title":"JAAD Int"},{"issue":"5","key":"1834_CR9","doi-asserted-by":"publisher","first-page":"663","DOI":"10.1684\/ejd.2012.1802","volume":"22","author":"X Ding","year":"2012","unstructured":"Ding X, Wang T, Shen Y, et al. Prevalence of psoriasis in China: a population-based study in six cities. Eur J Dermatol. 2012;22(5):663\u20137. https:\/\/doi.org\/10.1684\/ejd.2012.1802.","journal-title":"Eur J Dermatol"},{"issue":"4","key":"1834_CR10","doi-asserted-by":"publisher","first-page":"396","DOI":"10.2340\/00015555-2877","volume":"98","author":"JH Han","year":"2018","unstructured":"Han JH, Lee JH, Han KD, et al. Epidemiology and medication trends in patients with psoriasis: a nationwide population-based cohort study from Korea. Acta Derm Venereol. 2018;98(4):396\u2013400. https:\/\/doi.org\/10.2340\/00015555-2877.","journal-title":"Acta Derm Venereol"},{"issue":"6","key":"1834_CR11","doi-asserted-by":"publisher","first-page":"761","DOI":"10.5021\/ad.2017.29.6.761","volume":"29","author":"JY Lee","year":"2017","unstructured":"Lee JY, Kang S, Park JS, Jo SJ. Prevalence of psoriasis in Korea: a population-based epidemiological study using the Korean national health insurance database. Ann Dermatol. 2017;29(6):761\u20137. https:\/\/doi.org\/10.5021\/ad.2017.29.6.761.","journal-title":"Ann Dermatol"},{"key":"1834_CR12","unstructured":"National, regional, and worldwide epidemiology of psoriasis: systematic analysis and modelling study|The BMJ. Accessed December 15, 2025. https:\/\/www.bmj.com\/content\/369\/bmj.m1590"},{"issue":"4","key":"1834_CR13","doi-asserted-by":"publisher","first-page":"854","DOI":"10.1111\/bjd.16083","volume":"178","author":"L Chen","year":"2018","unstructured":"Chen L, Tsai TF. HLA-Cw6 and psoriasis. Br J Dermatol. 2018;178(4):854\u201362. https:\/\/doi.org\/10.1111\/bjd.16083.","journal-title":"Br J Dermatol"},{"key":"1834_CR14","unstructured":"Recategorization of Psoriasis Severity. International Psoriasis Council. Accessed May\u00a08, 2026. https:\/\/psoriasiscouncil.org\/ipc-resources\/disease-severity\/"},{"key":"1834_CR15","doi-asserted-by":"publisher","DOI":"10.1111\/bjd.13980","author":"B Strober","year":"2025","unstructured":"Strober B, et al. Prioritizing the global research agenda in psoriasis: an International Psoriasis Council Delphi consensus exercise. Br J Dermatol. 2025. https:\/\/doi.org\/10.1111\/bjd.13980.","journal-title":"Br J Dermatol"},{"issue":"12","key":"1834_CR16","doi-asserted-by":"publisher","first-page":"1579","DOI":"10.1111\/1346-8138.17471","volume":"51","author":"SE Choon","year":"2024","unstructured":"Choon SE, Foley PA, Asawanonda P, et al. Asia\u2013Pacific consensus recommendations on the management of generalized pustular psoriasis. J Dermatol. 2024;51(12):1579\u201395. https:\/\/doi.org\/10.1111\/1346-8138.17471.","journal-title":"J Dermatol"},{"issue":"1","key":"1834_CR17","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1111\/1346-8138.17444","volume":"52","author":"A Morita","year":"2025","unstructured":"Morita A, Okubo Y, Imafuku S, et al. Expert consensus on systemic therapy for plaque psoriasis with limited skin involvement in JAPAN: Results from a DELPHI study. J Dermatol. 2025;52(1):56\u201366. https:\/\/doi.org\/10.1111\/1346-8138.17444.","journal-title":"J Dermatol"},{"issue":"3","key":"1834_CR18","doi-asserted-by":"publisher","first-page":"100","DOI":"10.1177\/24755303231160683","volume":"8","author":"A Blauvelt","year":"2023","unstructured":"Blauvelt A, Gondo GC, Bell S, et al. Psoriasis involving special areas is associated with worse quality of life, depression, and limitations in the ability to participate in social roles and activities. J Psoriasis Psoriatic Arthritis. 2023;8(3):100\u20136. https:\/\/doi.org\/10.1177\/24755303231160683.","journal-title":"J Psoriasis Psoriatic Arthritis"},{"key":"1834_CR19","doi-asserted-by":"publisher","unstructured":"Moschogianis SF, Chisholm A, McKie S, Griffiths CEM, Elliott R, Kleyn CE. \u2018Ugh\u2026how do you catch that?\u2019: a qualitative study of the impact of psoriasis on social interactions. Clin Exp Dermatol. 2025;50(8):1606\u20131613. https:\/\/doi.org\/10.1093\/ced\/llaf146.","DOI":"10.1093\/ced\/llaf146"},{"issue":"7","key":"1834_CR20","doi-asserted-by":"publisher","first-page":"627","DOI":"10.3390\/life11070627","volume":"11","author":"L Salgado-Boquete","year":"2021","unstructured":"Salgado-Boquete L, Carrascosa JM, Llamas-Velasco M, Ruiz-Villaverde R, de la Cueva P, Belinch\u00f3n I. A new classification of the severity of psoriasis: what\u2019s moderate psoriasis? Life. 2021;11(7):627. https:\/\/doi.org\/10.3390\/life11070627.","journal-title":"Life"},{"issue":"1","key":"1834_CR21","doi-asserted-by":"publisher","first-page":"2626219","DOI":"10.1080\/09546634.2026.2626219","volume":"37","author":"A Costanzo","year":"2026","unstructured":"Costanzo A, Bardazzi F, Burlando M, et al. Toward the definition of moderate psoriasis: an expert opinion. J Dermatol Treat. 2026;37(1):2626219. https:\/\/doi.org\/10.1080\/09546634.2026.2626219.","journal-title":"J Dermatol Treat"},{"key":"1834_CR22","unstructured":"Ministry of Health Malaysia. The eleventh report of the Malaysian psoriasis registry. Published online 2021. https:\/\/www.dermatology.org.my\/DermReg\/AnnualReports\/MPR_REPORT_2007-2019.pdf. Accessed 4 Nov 2025."},{"issue":"4","key":"1834_CR23","doi-asserted-by":"publisher","first-page":"1249","DOI":"10.1007\/s13555-021-00544-6","volume":"11","author":"C Leonardi","year":"2021","unstructured":"Leonardi C, See K, Gallo G, et al. Psoriasis severity assessment combining physician and patient reported outcomes: the optimal psoriasis assessment tool. Dermatol Ther. 2021;11(4):1249\u201363. https:\/\/doi.org\/10.1007\/s13555-021-00544-6.","journal-title":"Dermatol Ther"},{"key":"1834_CR24","unstructured":"PBS. Pharmaceutical Benefits Scheme\u2014The use of biologics in the treatment of severe chronic plaque psoriasis. https:\/\/www.pbs.gov.au\/reviews\/biologics-files\/final-cpp-report-tor1.PDF. Accessed 4 Nov 2025."},{"key":"1834_CR25","unstructured":"Bagel J. Treat to target in psoriasis: a real-world experience with biologics and adjunctive topical therapy. J Drugs Dermatol. 2018;17(8):918. https:\/\/jddonline.com\/articles\/treat-to-target-in-psoriasis-a-real-world-experience-with-biologics-and-adjunctive-topical-therapy-S1545961618P0918X\/. Accessed Nov 4, 2025."},{"key":"1834_CR26","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2025.08.116","author":"BE Strober","year":"2025","unstructured":"Strober BE, Blauvelt A, van de Kerkhof PCM, et al. Establishing consensus on defining failure of topical therapy in psoriasis: Recommendations from the International Psoriasis Council. J Am Acad Dermatol. 2025. https:\/\/doi.org\/10.1016\/j.jaad.2025.08.116.","journal-title":"J Am Acad Dermatol"},{"issue":"1","key":"1834_CR27","doi-asserted-by":"publisher","first-page":"372","DOI":"10.1016\/j.jaad.2025.08.116","volume":"94","author":"BE Strober","year":"2026","unstructured":"Strober BE, Blauvelt A, van de Kerkhof PCM, et al. Establishing consensus on defining failure of topical therapy in psoriasis: recommendations from the International Psoriasis Council. J Am Acad Dermatol. 2026;94(1):372\u20135. https:\/\/doi.org\/10.1016\/j.jaad.2025.08.116.","journal-title":"J Am Acad Dermatol"},{"issue":"8","key":"1834_CR28","doi-asserted-by":"publisher","first-page":"776","DOI":"10.1080\/09546634.2019.1623371","volume":"31","author":"MT Svendsen","year":"2020","unstructured":"Svendsen MT, Feldmann S, Tiedemann SN, S\u00f8rensen ASS, Rivas CMR, Andersen KE. Improving psoriasis patients\u2019 adherence to topical drugs: a systematic review. J Dermatol Treat. 2020;31(8):776\u201385. https:\/\/doi.org\/10.1080\/09546634.2019.1623371.","journal-title":"J Dermatol Treat"},{"issue":"6","key":"1834_CR29","doi-asserted-by":"publisher","first-page":"241","DOI":"10.37349\/emd.2023.00026","volume":"1","author":"S Akarsu","year":"2023","unstructured":"Akarsu S. How should we do in the selection and follow-up of systemic conventional treatments in psoriasis? Explor Musculoskelet Dis. 2023;1(6):241\u201356. https:\/\/doi.org\/10.37349\/emd.2023.00026.","journal-title":"Explor Musculoskelet Dis"},{"issue":"10","key":"1834_CR30","doi-asserted-by":"publisher","first-page":"2016","DOI":"10.1111\/jdv.19236","volume":"37","author":"K Sch\u00e4kel","year":"2023","unstructured":"Sch\u00e4kel K, Reich K, Asadullah K, et al. Early disease intervention with guselkumab in psoriasis leads to a higher rate of stable complete skin clearance (\u2018clinical super response\u2019): week\u00a028 results from the ongoing phase\u00a0IIIb randomized, double-blind, parallel-group, GUIDE study. J Eur Acad Dermatol Venereol. 2023;37(10):2016\u201327. https:\/\/doi.org\/10.1111\/jdv.19236.","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"11","key":"1834_CR31","doi-asserted-by":"publisher","first-page":"1665","DOI":"10.1111\/1346-8138.16072","volume":"48","author":"Y Tada","year":"2021","unstructured":"Tada Y, Jo SJ, Huang YH, et al. Uncovering the unmet needs among psoriasis patients in the Asia\u2013Pacific region. J Dermatol. 2021;48(11):1665\u201374. https:\/\/doi.org\/10.1111\/1346-8138.16072.","journal-title":"J Dermatol"},{"issue":"10","key":"1834_CR32","doi-asserted-by":"publisher","first-page":"1293","DOI":"10.1111\/ijd.17236","volume":"63","author":"V Wan","year":"2024","unstructured":"Wan V, Habibi A, Mija LA, Abdi P, Selvakumar R, Mukovozov I. Disparities and barriers to the access of biologics in moderate-to-severe adult psoriasis. Int J Dermatol. 2024;63(10):1293\u2013301. https:\/\/doi.org\/10.1111\/ijd.17236.","journal-title":"Int J Dermatol"},{"key":"1834_CR33","doi-asserted-by":"publisher","unstructured":"Azizam NA, Hussain M, Nauenberg E, Ang WC, Azzeri A, Smith J. Cost-effectiveness analysis of biologic sequential treatments for moderate-to-severe psoriasis: a Malaysian healthcare system perspective. PLoS One. 2024;19(9):e0307234. https:\/\/doi.org\/10.1371\/journal.pone.0307234.","DOI":"10.1371\/journal.pone.0307234"},{"issue":"3","key":"1834_CR34","doi-asserted-by":"publisher","first-page":"173","DOI":"10.5021\/ad.22.216","volume":"35","author":"SJ Jo","year":"2023","unstructured":"Jo SJ, Baek YS, Kim TG, et al. Basic therapeutic approach for patients with plaque psoriasis: Korean expert consensus using the modified delphi method. Ann Dermatol. 2023;35(3):173\u201382. https:\/\/doi.org\/10.5021\/ad.22.216.","journal-title":"Ann Dermatol"},{"key":"1834_CR35","unstructured":"Modified Delphi Process|Family & Preventive Medicine|University of Utah School of Medicine. February 21, 2024. https:\/\/medicine.utah.edu\/dfpm\/public-health\/research\/research-groups\/ohleh\/research\/phepr\/modified-delphi-process. Accessed Nov 4, 2025."},{"key":"1834_CR36","unstructured":"Khodyakov D, Grant S, Kroger J, Bauman M. RAND methodological guidance for conducting and critically appraising Delphi panels. ResearchGate. https:\/\/www.researchgate.net\/publication\/378231866_RAND_Methodological_Guidance_for_Conducting_and_Critically_Appraising_Delphi_Panels. Accessed Nov 4, 2025."},{"issue":"12","key":"1834_CR37","doi-asserted-by":"publisher","first-page":"2573","DOI":"10.1038\/s41366-018-0313-9","volume":"43","author":"C Vogel","year":"2019","unstructured":"Vogel C, Zwolinsky S, Griffiths C, Hobbs M, Henderson E, Wilkins E. A Delphi study to build consensus on the definition and use of big data in obesity research. Int J Obes 2005. 2019;43(12):2573\u201386. https:\/\/doi.org\/10.1038\/s41366-018-0313-9.","journal-title":"Int J Obes 2005"},{"key":"1834_CR38","unstructured":"The Delphi method. BPS. https:\/\/www.bps.org.uk\/psychologist\/delphi-method. Accessed Nov 4, 2025."},{"issue":"3","key":"1834_CR39","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3310\/hta2030","volume":"2","author":"MK Murphy","year":"1998","unstructured":"Murphy MK, Black NA, Lamping DL, et al. Consensus development methods, and their use in clinical guideline development. Health Technol Assess. 1998;2(3):1\u201388.","journal-title":"Health Technol Assess"}],"container-title":["Dermatology and Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13555-026-01834-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s13555-026-01834-7","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13555-026-01834-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,9]],"date-time":"2026-09-09T19:21:28Z","timestamp":1788981688000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s13555-026-01834-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,1]]},"references-count":39,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2026,9]]}},"alternative-id":["1834"],"URL":"https:\/\/doi.org\/10.1007\/s13555-026-01834-7","relation":{},"ISSN":["2193-8210","2190-9172"],"issn-type":[{"value":"2193-8210","type":"print"},{"value":"2190-9172","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,1]]},"assertion":[{"value":"2 April 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 June 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 July 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 August 2026","order":5,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Update","order":6,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Author affiliation for Siew Eng Choon and Tsen Fang Tsai updated.","order":7,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Yoo Sang Baek has served as a scientific adviser, clinical study investigator, and\/or a speaker for AbbVie, Bristol Myers Squibb, Eli Lilly and Company, Janssen, Kolon Pharma, Novartis, UCB Pharma, and Yuhan. Siew Eng Choon had served as a consultant, advisory board member, and\/or speaker for AbbVie, Almirall, Boehringer Ingelheim, Johnson & Johnson and Novartis. Peter Anthony Foley has received fees, honoraria, grants, and\/or research funding as a speaker, investigator, advisory board member, and\/or consultant from AbbVie, Akaal, Almirall, Alumis, Amgen, Apogee, Arcutis, Argenx, Arrotex\/Juniper, Aslan, AstraZeneca, Avalo, Boehringer Ingelheim, Botanix Pharmaceuticals, Bristol Myers Squibb, Celgene, Celtaxsys, Claruvis, CSL, Cutanea, Dermira, Eli Lilly and Company, Evelo, Galderma, Genentech, Geneseq, GenesisCare, GlaxoSmithKline, Hexima, Incyte, Janssen, Kymab, LEO Pharma, L\u2019Oreal, Mayne Pharma, MedImmune, Merck, Novartis, Oruka, Pfizer, Regeneron, Reistone Biopharma, Roche, Sanofi Genzyme, Sun Pharma, Takeda, Teva, UCB Pharma, Valeant Pharmaceuticals, and ZaiLab. Tsen-Fang Tsai has conducted clinical trials and received honoraria for serving as a consultant for AbbVie, AnaptysBio, Boehringer Ingelheim, Bristol Myers Squibb, Celgene, Eli Lilly, Galderma, GSK, Janssen-Cilag, LEO Pharma, Merck Sharp & Dohme, Novartis International, Pfizer, PharmaEssentia, Sanofi, Sun Pharma, Takeda and UCB Pharma. Tsen-Fang Tsai is an Editorial Board member of\n                      Dermatology and Therapy\n                      . Tsen-Fang Tsai was not involved in the selection of peer reviewers for the manuscript nor any of the subsequent editorial decisions. Jianzhong Zhang has served as a consultant, investigator and\/or speaker for: AbbVie, Eli Lilly, LEO Pharma, Novartis, Pfizer, Sanofi, Takeda, Bristol Myers Squibb, Keymed, Thederma, Akesobio, Kintor, Longwood, Cutia, Shenzhen Kangzhe, InventisBio, Genrix Bio, 3SBio, Jiangsu Hengrui Medicine, Xian Janssen, Zelgen, TopAlliance, Jemincare, Highlight, Hangzhou Zhongmei Huadong, Innovent Biologics. Viatris. Yukie Yamaguchi declares research grants, and\/or consulting fees, and\/or speaker fees from AbbVie, Amgen, AstraZeneca, Boehringer Ingelheim, Eli Lilly, Fuji Pharma, Janssen, Kyowa Kirin, LEO Pharma, Maruho, Novartis, Sun Pharmaceutical Industries, Torii Pharmaceutical and UCB Japan.","order":1,"name":"Ethics","label":"Conflict of Interest","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study was conducted as a modified Delphi consensus exercise involving dermatology experts from Australia, China, Japan, Malaysia, South Korea, and Taiwan. The study did not involve patients, clinical interventions, biological samples, or identifiable personal health data. All participants took part in their professional capacity. In view of the minimal-risk nature of the study, formal institutional review board approval was not sought. The study was conducted in accordance with applicable local ethical, regulatory, and data protection requirements. Electronic informed consent was obtained from all steering committee and panel members prior to participation in the first round. Participants were informed that participation was entirely voluntary and that they could withdraw at any time. All study data were stored and managed in compliance with applicable privacy and data protection regulations, including relevant local legal requirements.","order":2,"name":"Ethics","label":"Ethical Approval","group":{"name":"EthicsHeading","label":"Declarations"}}]}}